214 drugs were taken off the network, what happened?

【Pharmaceutical Network Industry News】Recently, the Shandong Provincial Public Resources Exchange Center issued a notice on the withdrawal of medical consumables and in vitro diagnostic reagent products, and the attached announcement form (third batch) of the network removal products shows that a total of 214 products have been withdrawn
。 From the perspective of the reasons for the withdrawal of the network, 58 of them applied for the withdrawal of the network due to "price filling errors", 25 applied for the withdrawal of the network due to "no market demand for the product", 16 applied for the withdrawal of the network due to "repeated declaration", in addition, some drugs were due to "raw material supply and the company's production line adjustment, can not meet the supply, apply for withdrawal", "registration certificate cancellation, application for withdrawal", "product stoppage, application for withdrawal" and so on
。 According to the announcement, according to the Opinions of the Shandong Provincial Medical Security Bureau on Strengthening the Centralized Procurement of Drugs and Medical Consumables (Lu Yibao Fa [2019] No
.
66), if a manufacturer applies for the withdrawal of the network, it shall not be re-listed within two years higher than the original listing price.
Under the normalization of centralized procurement, drug price reduction has become a trend, many pharmaceutical companies have been eliminated, there are also a large number of cases of drug withdrawal and hanging on the network, in addition to Shandong Province, according to incomplete statistics, this year Gansu, Anhui, Guangxi, Guizhou, Ningxia, etc.
have successively issued notices for the withdrawal of drugs on the Internet, among which the withdrawal of drugs due to unreasonable drug prices has attracted much attention
。 On November 12, 2020, the National Health Insurance Bureau pointed out in a reply that while promoting drug prices to return to a reasonable level through quantitative procurement, the National Health Insurance Bureau also comprehensively uses monitoring and early warning, letter inquiries and interviews, reminders and warnings, cost investigations, credit evaluation, information disclosure and other means to establish and improve the normalization of drug price supervision mechanisms and promote operators to strengthen price self-discipline
。 For example, Jilin Province issued the Notice on Announcing the Dynamic Linkage Results of the Centralized Procurement of Non-selected Drugs in the "Six Provinces and Two Regions" and the Notice on Announcing the Fourth Batch of National Organizations and the Drugs with the Same or Similar Chemical Active Ingredients in Selected Varieties of Selected Varieties in the "Six Provinces and Two Regions" to Linkage the Lowest Provincial Winning Bid (Hanging Network) Price in the Country"; The Sichuan Provincial Pharmaceutical and Equipment Bidding and Procurement Service Center has published a number of notices
on its page about enterprises submitting applications for drug price reduction and lowering the reference prices of some drugs.
In addition, some provinces have even withdrawn and reported
drugs with unreasonable prices.
For example, in June this year, the Hubei Provincial Pharmaceutical Price and Bidding and Procurement Management Service Network issued an announcement that in the centralized procurement of proprietary Chinese medicines in 19 provinces (autonomous regions and municipalities) led by Hubei Province, a total of 227 drugs under the same drug name will be suspended from the network
.
According to the announcement, the reasons why these drugs will be suspended include failure to make information declarations and price adjustments as required within the specified time limit, failure to submit declaration materials and meet the declaration conditions and not included in the supply list
of selected enterprises.
Among them, the failure of enterprises to voluntarily declare is the main reason
.
For another example, on February 8, the Hunan Provincial Public Resources Exchange Center announced the "Declaration Results of Some Drug Price Correction and Limited-Price Hanging Enterprises", including the gastrointestinal drug famotidine and the cardiovascular and cerebrovascular drug Chuanxiongzine, only 18 of the 341 product specifications of 10 generic names were listed on the net, and the other 323 product regulations were all withdrawn, and the product regulations of the removed network involved more than 100 enterprises
。 Regarding the reasons for the withdrawal of the network, the Hunan Medical Insurance Bureau notified that the above 10 drugs have the phenomenon
of large differences in the prices of the same hanging network directory (especially the large price difference in different periods), obvious inconsistency in price quality, more mutual complaints, and real-name reported prices.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.